Hospitalized cohort characteristics
| . | SARS-CoV-2 negative N=50 393 . | COVID-19 vaccine breakthrough N=3443 . | COVID-19 unvaccinated N=10 084 . |
|---|---|---|---|
| Age, years | |||
| Mean (SD) | 59 (20) | 60(20) | 55 (18) |
| Sex, n (%) | |||
| Female | 28 795 (57.1) | 1904 (55.3) | 5092 (50.5) |
| Male | 21 598 (42.9) | 1539 (44.7) | 4992 (49.5) |
| Race/ethnicity, n (%) | |||
| African American | 3980 (7.9) | 337 (9.8) | 1168 (11.6) |
| Asian | 8819 (17.5) | 516 (15.0) | 1325 (13.1) |
| Hispanic | 9514 (18.9) | 928 (27.0) | 3246 (32.2) |
| White | 24 609 (48.8) | 1416 (41.1) | 3653 (36.2) |
| Missing/other | 3471 (6.9) | 246 (7.1) | 692 (6.9) |
| Body mass index, n (%) | |||
| Healthy weight | 14 342 (28.5) | 772 (22.4) | 1269 (12.6) |
| Overweight | 15 721 (31.2) | 1014 (29.5) | 2661 (26.4) |
| Obese | 17 599 (34.9) | 1521 (44.2) | 5568 (55.2) |
| Underweight | 1396 (2.8) | 64 (1.9) | 87 (0.9) |
| Missing | 1335 (2.7) | 72 (2.1) | 499 (5.0) |
| Median (IQR) | 28 (24-32) | 29 (25-34) | 31 (27-37) |
| Comorbidities, n (%) | |||
| Hypertension | 22 634 (44.9) | 1695 (49.2) | 4448 (44.1) |
| Diabetes | 12 473 (24.8) | 1147 (33.3) | 3095 (30.7) |
| Chronic kidney disease | 10 699 (21.2) | 832 (24.2) | 1421 (14.1) |
| COPD | 11 981 (23.8) | 873 (25.4) | 2333 (23.1) |
| Congestive heart failure | 8098 (16.1) | 448 (13.0) | 694 (6.9) |
| Malignancy | 6790 (13.5) | 397 (11.5) | 581 (5.8) |
| Leukemia/lymphoma/myeloma | 1193 (2.4) | 110 (3.2) | 115 (1.1) |
| Peripheral vascular disease | 18 058 (35.8) | 1318 (38.3) | 2163 (21.5) |
| Rheumatologic disease | 1342 (2.7) | 120 (3.5) | 166 (1.7) |
| Transplant | 679 (1.4) | 129 (3.8) | 97 (1.0) |
| Interstitial lung disease | 1361 (2.7) | 94 (2.7) | 211 (2.1) |
| History of smoking, n (%) | 21 895 (43.5) | 1612 (46.8) | 3776 (37.5) |
| Lab test setting, n (%) | |||
| Outpatient | 23 427 (46.5) | 1795 (52.1) | 6045 (60.0) |
| Inpatient | 26 966 (53.5) | 1648 (47.9) | 4039 (40.1) |
| ICU level of care, n (%) | 4103 (8.1) | 236 (6.9) | 918 (9.1) |
| IMPROVE VTE Score (IQR) | 1 (0-1) | 1 (0-1) | 1 (0-1) |
| Hospital length of stay, days (IQR) | 2 (0-4) | 3 (1-5) | 4 (2-7) |
| COVID-19 period, n (%) | |||
| Pre-Delta | 20 644 (41.0) | 33 (1.0) | 4738 (47.0) |
| Delta | 14 531 (28.8) | 1029 (29.9) | 3736 (37.1) |
| Omicron | 15 218 (30.2) | 2381 (69.2) | 1610 (16.0) |
| Vaccine type, n (%) | N=27 984 | N=3443 | |
| Pfizer/BioNTech | 15 691 (56.1) | 2042 (59.3) | |
| Moderna | 10 764 (38.5) | 1010 (29.3) | |
| Janssen | 1527 (5.5) | 391 (11.4) |
| . | SARS-CoV-2 negative N=50 393 . | COVID-19 vaccine breakthrough N=3443 . | COVID-19 unvaccinated N=10 084 . |
|---|---|---|---|
| Age, years | |||
| Mean (SD) | 59 (20) | 60(20) | 55 (18) |
| Sex, n (%) | |||
| Female | 28 795 (57.1) | 1904 (55.3) | 5092 (50.5) |
| Male | 21 598 (42.9) | 1539 (44.7) | 4992 (49.5) |
| Race/ethnicity, n (%) | |||
| African American | 3980 (7.9) | 337 (9.8) | 1168 (11.6) |
| Asian | 8819 (17.5) | 516 (15.0) | 1325 (13.1) |
| Hispanic | 9514 (18.9) | 928 (27.0) | 3246 (32.2) |
| White | 24 609 (48.8) | 1416 (41.1) | 3653 (36.2) |
| Missing/other | 3471 (6.9) | 246 (7.1) | 692 (6.9) |
| Body mass index, n (%) | |||
| Healthy weight | 14 342 (28.5) | 772 (22.4) | 1269 (12.6) |
| Overweight | 15 721 (31.2) | 1014 (29.5) | 2661 (26.4) |
| Obese | 17 599 (34.9) | 1521 (44.2) | 5568 (55.2) |
| Underweight | 1396 (2.8) | 64 (1.9) | 87 (0.9) |
| Missing | 1335 (2.7) | 72 (2.1) | 499 (5.0) |
| Median (IQR) | 28 (24-32) | 29 (25-34) | 31 (27-37) |
| Comorbidities, n (%) | |||
| Hypertension | 22 634 (44.9) | 1695 (49.2) | 4448 (44.1) |
| Diabetes | 12 473 (24.8) | 1147 (33.3) | 3095 (30.7) |
| Chronic kidney disease | 10 699 (21.2) | 832 (24.2) | 1421 (14.1) |
| COPD | 11 981 (23.8) | 873 (25.4) | 2333 (23.1) |
| Congestive heart failure | 8098 (16.1) | 448 (13.0) | 694 (6.9) |
| Malignancy | 6790 (13.5) | 397 (11.5) | 581 (5.8) |
| Leukemia/lymphoma/myeloma | 1193 (2.4) | 110 (3.2) | 115 (1.1) |
| Peripheral vascular disease | 18 058 (35.8) | 1318 (38.3) | 2163 (21.5) |
| Rheumatologic disease | 1342 (2.7) | 120 (3.5) | 166 (1.7) |
| Transplant | 679 (1.4) | 129 (3.8) | 97 (1.0) |
| Interstitial lung disease | 1361 (2.7) | 94 (2.7) | 211 (2.1) |
| History of smoking, n (%) | 21 895 (43.5) | 1612 (46.8) | 3776 (37.5) |
| Lab test setting, n (%) | |||
| Outpatient | 23 427 (46.5) | 1795 (52.1) | 6045 (60.0) |
| Inpatient | 26 966 (53.5) | 1648 (47.9) | 4039 (40.1) |
| ICU level of care, n (%) | 4103 (8.1) | 236 (6.9) | 918 (9.1) |
| IMPROVE VTE Score (IQR) | 1 (0-1) | 1 (0-1) | 1 (0-1) |
| Hospital length of stay, days (IQR) | 2 (0-4) | 3 (1-5) | 4 (2-7) |
| COVID-19 period, n (%) | |||
| Pre-Delta | 20 644 (41.0) | 33 (1.0) | 4738 (47.0) |
| Delta | 14 531 (28.8) | 1029 (29.9) | 3736 (37.1) |
| Omicron | 15 218 (30.2) | 2381 (69.2) | 1610 (16.0) |
| Vaccine type, n (%) | N=27 984 | N=3443 | |
| Pfizer/BioNTech | 15 691 (56.1) | 2042 (59.3) | |
| Moderna | 10 764 (38.5) | 1010 (29.3) | |
| Janssen | 1527 (5.5) | 391 (11.4) |
Data are presented as number (%) unless otherwise specified.
COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.